

Info Sheet for Technical description

No. 0021

Organization

* Mandatory fields

Name of Organization*	Celaid Therapeutics Inc.	
Address, City, States, Zip, Country*	Utokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8485, Japan	
URL	https://celaidtx.com/en/about/	
Brief Descriptions of Organization* (Approx. 100 words)	Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases.	
Contact address	Name*	Yusuke Inoue
	Department* / Position	Board Director, COO/CFO
	E-mail* / TEL	yusuke.inoue@celaidtx.com

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☒ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☒ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☐ Yes	Please let us know if someone has an interest in our technology.
☒ No	bdcontact@celaidtx.com

Filled in by*

Date*

Celaid Therapeutics Inc.
22-Jul-25

Sheet [C] Platform Technologies *that are not included in Group B***Info Sheet for Technical overview**

No. C-0021

* Mandatoty fields

Title***Hematopoietic Stem Cell Expansion Platform for Advanced Cell and Gene Therapy Products****Description*****🔓 Unlocking the Potential of Hematopoietic Stem Cells (HSCs): Partnering with Celaid's Expansion Platform**

Hematopoietic stem cell (HSC) therapies hold great promise, but their full potential is limited by the challenges of expanding functional HSCs efficiently and affordably. Celaid Therapeutics, founded by pioneers in HSC biology, offers a cutting-edge platform that addresses this challenge—opening new possibilities for cell and gene therapies. We invite strategic partners to explore licensing and collaboration opportunities.

🔑 Breakthrough HSC Expansion Technology

Celaid has developed proprietary media, protocols, and know-how for ex vivo expansion of undifferentiated HSCs from iPSC-, cord blood-, peripheral blood-, and bone marrow-derived CD34+ cells. The expanded HSCs retain stemness and their ability to differentiate into all hematopoietic lineages, including T cells, NK cells, myeloid and erythroid cells.

Key advantages include:

- High yield of functional, undifferentiated HSCs
- In vivo engraftment capacity in immunodeficient mice
- Gene-editing compatibility
- Scalable, GMP-compliant, and cost-efficient manufacturing

💡 Validated Through Strategic Partnerships

Celaid has active collaborations with biotechs, pharmas, and academic institutions worldwide. These alliances confirm the platform's therapeutic value.

The company recently raised ¥1.2B (USD 7.8M) in Series A funding from The University of Tokyo Edge Capital Partners (UTEC), Osaka University Venture Capital (OUVC), and others, and secured up to ¥2.7B (USD 19M) in the Japanese Agency for Medical Research and Development (AMED) grants for its lead program, CLD-001—an expanded HSC therapy for pediatric non-malignant diseases. IND preparation is underway in the U.S., highlighting our regulatory readiness to support partner programs.

💖 Seeking New Collaborations

We welcome partnerships with biotech/pharma companies, CDMOs, and research institutions aiming to apply our HSC expansion system in their therapies or manufacturing pipelines.

✉ Contact us at "bdcontact@celaidtx.com" to learn more or explore collaborations.

Filled in by*

Celaid Therapeutics Inc.

Date*

2025/7/22